FP
Fletcher Payne
Senior Vice President, Chief Financial Officer & Chief Business Officer
Aptose BiosciencesTherapeutic Areas
Aptose Biosciences Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Tuspetinib (HM43239) | Relapsed/Refractory AML | Phase 1/2 |
| Luxeptinib (CG-806) | Relapsed/Refractory B-cell malignancies (CLL, NHL) | Phase 1a/b |
Leadership Team at Aptose Biosciences
WG
William G. Rice, Ph.D.
Chairman of the Board, President & Chief Executive Officer
RB
Rafael Bejar, M.D., Ph.D.
Senior Vice President, Chief Medical Officer
DR
Denis R. Burger, Ph.D.
Board Member, Lead Director
EM
Erich M. Platzer, M.D., Ph.D.
Board Member
BD
Brian Druker, M.D.
Scientific Advisory Board Member